Physician profile
Darlene King
NPI 1821750548
$1,051.76
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $827 · 2023: $19.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $376.71 | 2021-2022 | |
| Mylan Specialty L.P. | $175.35 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.73 | 2021-2022 | |
| Grifols USA, LLC | $100.90 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $85.40 | 2022 | |
| Glaxosmithkline, LLC. | $62.92 | 2022 | |
| Genzyme Corporation | $40.73 | 2022 | |
| Baxter Healthcare | $28.36 | 2022 | |
| Vapotherm INC | $24.73 | 2022 | |
| Novo Nordisk INC | $19.11 | 2023 | Wegovy |
| Electromed, INC. | $13.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darlene King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.